BRIACELL THERAPEUTICS CORP. Amortisation Expense
BRIACELL THERAPEUTICS CORP. (BCTX) reported Amortisation Expense of $3.82 thousand for the 3-month period ending 2022-04-30, per its 6-K filed 2022-06-13.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:AmortisationExpense · last filed 2022-06-13
- BRIACELL THERAPEUTICS CORP. amortisation expense for the quarter ending 2022-04-30 was $3.82K, a 0.08% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. amortisation expense for the quarter ending 2022-01-31 was $3.82K, a 0.13% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. amortisation expense for the quarter ending 2021-07-31 was $3.81K.
- BRIACELL THERAPEUTICS CORP. amortisation expense for the quarter ending 2021-04-30 was $3.81K.
| Period end | Amortisation Expense 3 month | Amortisation Expense 6 month | Amortisation Expense 9 month | Amortisation Expense 12 month |
|---|---|---|---|---|
| 2022-04-30 | $3.82K 6-K · filed 2022-06-13 | $7.64K derived: sum of 2 quarters · filed 2022-06-13 | $11.45K 6-K · filed 2022-06-13 | |
| 2022-01-31 | $3.82K 6-K · filed 2022-03-15 | $7.64K 6-K · filed 2022-03-15 | ||
| 2021-07-31 | $3.81K derived: 40-F/A 12 month − 6-K 9 month · filed 2021-11-16 | $7.63K derived: sum of 2 quarters · filed 2022-06-13 | $11.44K derived: sum of 3 quarters · filed 2022-06-13 | $15.26K 40-F/A · filed 2021-11-16 |
| 2021-04-30 | $3.81K 6-K · filed 2022-06-13 | $7.63K derived: sum of 2 quarters · filed 2022-06-13 | $11.44K 6-K · filed 2022-06-13 | |
| 2021-01-31 | $3.81K 6-K · filed 2022-03-15 | $7.63K 6-K · filed 2022-03-15 | ||
| 2020-07-31 | $15.26K 40-F/A · filed 2021-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |